Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy

Leuk Lymphoma. 2017 Nov;58(11):2748-2751. doi: 10.1080/10428194.2017.1312374. Epub 2017 Apr 10.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acquired Immunodeficiency Syndrome / complications*
  • Acquired Immunodeficiency Syndrome / drug therapy*
  • Adult
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Central Nervous System Neoplasms / drug therapy*
  • Central Nervous System Neoplasms / etiology*
  • Drug Resistance, Viral
  • Female
  • Humans
  • Lenalidomide
  • Lymphoma, AIDS-Related / drug therapy*
  • Thalidomide / administration & dosage
  • Thalidomide / analogs & derivatives
  • Treatment Outcome

Substances

  • Thalidomide
  • Lenalidomide